Please assess the completion status of the following clinical trial:

Trial Title: The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CF as defined by clinical features of CF and a documented sweat chloride \> 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations~* Informed consent and verbal assent (as appropriate) has been provided by the subject's parent or legal guardian and the subject~* 6-18 years of age at enrolment~* Able to perform reproducible spirometry~* Clinically stable at enrolment~* Ability to comply with medication use, study visits and study procedures as judged by the site investigator~* FEV1 % predicted \> 70 % as calculated by the Wang reference equations~Exclusion Criteria:~* Respiratory culture positive for:~  * NTM within past year or AFB positive at screening (sputum only)~ * B. cepacia complex within past year or at screening~* Use of intravenous antibiotics or oral quinolones within 14 days of screening~* Investigational drug use within 30 days of screening~* History of alcohol, illicit drug or medication abuse within 1 year of screening~* Other major organ dysfunction excluding pancreatic dysfunction~* History of lung transplantation or currently on lung transplant list~* Physical findings at screening that would compromise the safety of the participant or the quality of the study data

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
- 2 (Type: OTHER): This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).